Abstract

Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrugresistant (MDR) tuberculosis (TB). With this treatment, however, some patients remain at high risk for an unfavorable treatment outcome. The present study was undertaken to compare sputum culture conversion rate at the end of 24 weeks (I.P.) of bedaquiline containing antitubercular regimen with bedaquiline not containing antitubercular regimen. Method: Total 57 patients of MDR-TB and XDR-TB who were started on antitubercular regimen in the period between 2018 to 2020 were enrolled in the study. Patients were divided into bedaquiline containing antitubercular regimen and nonbedaquiline antitubercular regimen. Follow up sputum culture were done on 3rd, 4th, 5th, 6th month of treatment. Sputum sample is collected and send for culture in RNTCP accredited lab. Sputum culture conversion rate of bedaquiline regimen was compared with nonbedaquiline regimen. Results: Patients with bedaquiline (BDQ) containing regimen were 40 (70.18%) and 17 (29.82%) patients were seen on without BDQ containing regimen. Out of 57, 24 (60%) male patients were on bedaquiline (BDQ) and 12 (70.58%) were on without bedaquiline regimen, 16(40%) female patients were on BDQ and without BDQ there were only 5 (29%). Out of 40 patients who were started on BDQ containing regimen, 39 patients came negative at the end of 6th month, culture conversion rate was 97.5%. Whereas out of 17 patients who were started on without BDQ containing regimen, 13 patients came negative at the end of 6th month, culture conversion rate was 76.47%. Conclusion: BDQ containing regimen has significantly more culture conversion rate at the end of 24 weeks (Intensive phase) as compared to non BDQ containing regimen

Description

.